NEO vs TLX: fair value comparison
NeoGenomics, Inc. and Telix Pharmaceuticals Limited · Updated 2026-10-19
NEO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. TLX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NEO currently ranks higher by quality score.
| NEO | TLX | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $16.65 | $10.69 |
| 12-month range | $7.19–$19.91 | $6.41–$12.83 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #128 of 301 Healthcare | #130 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: NEO fair value analysis · TLX fair value analysis